Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)

Abstract

Introduction: Tachykinins are endogenous peptide neurotransmitters, acting through the NK1, NK2 and NK3 receptors, at central and peripheral level. At peripheral level, they are involved in contraction of smooth muscle, secretion of water and ion from epithelia, as well as modulation of visceral pain sensitivity. Tachykinin NK2 receptor antagonists have the potential to be useful in the treatment of various gastrointestinal, genitourinary and CNS diseases.

Areas covered: In this review, an overview of the patenting activity in the last 5 years is provided. Patents from different companies and research groups are discussed for their novelty and evaluated in relation to proposed indications and clinical studies. Relevant biological data are also presented. Patents claiming new therapeutic indications are included in a dedicated section.

Expert opinion: Although there is still no tachykinin NK2 receptor antagonist approved for use in human therapy, research in the field is still proposing new compounds and possible uses. A number of candidates are being evaluated in Phase II clinical studies, in indications ranging from gastrointestinal disorders to inflammatory diseases. The results of these studies will indicate the role of tachykinin NK2 receptor antagonists in human therapy.

Keywords:

• asthma
• atopic dermatitis
• depression
• infant colic
• inflammation
• irritable bowel syndrome
• neurokinin A
• NK2 receptor antagonists
• tachykinins

Acknowledgement

The author wishes to thank Laura Quartara, Menarini Ricerche, for her continuous support and for helpful discussions.

Notes

This box summarizes key points contained in the article.